618 related articles for article (PubMed ID: 18068260)
1. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
Pouton CW; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
[TBL] [Abstract][Full Text] [Related]
2. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
Chen ML
Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
[TBL] [Abstract][Full Text] [Related]
3. Approaches for the development of solid and semi-solid lipid-based formulations.
Jannin V; Musakhanian J; Marchaud D
Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
5. Oral lipid-based formulations.
Hauss DJ
Adv Drug Deliv Rev; 2007 Jul; 59(7):667-76. PubMed ID: 17618704
[TBL] [Abstract][Full Text] [Related]
6. Enhancing intestinal drug solubilisation using lipid-based delivery systems.
Porter CJ; Pouton CW; Cuine JF; Charman WN
Adv Drug Deliv Rev; 2008 Mar; 60(6):673-91. PubMed ID: 18155801
[TBL] [Abstract][Full Text] [Related]
7. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
8. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs.
Müllertz A; Ogbonna A; Ren S; Rades T
J Pharm Pharmacol; 2010 Nov; 62(11):1622-36. PubMed ID: 21039546
[TBL] [Abstract][Full Text] [Related]
9. What determines drug solubility in lipid vehicles: is it predictable?
Rane SS; Anderson BD
Adv Drug Deliv Rev; 2008 Mar; 60(6):638-56. PubMed ID: 18089295
[TBL] [Abstract][Full Text] [Related]
10. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW;
J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238
[TBL] [Abstract][Full Text] [Related]
11. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
Pouton CW
Eur J Pharm Sci; 2006 Nov; 29(3-4):278-87. PubMed ID: 16815001
[TBL] [Abstract][Full Text] [Related]
12. Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS).
Rahman MA; Hussain A; Hussain MS; Mirza MA; Iqbal Z
Drug Dev Ind Pharm; 2013 Jan; 39(1):1-19. PubMed ID: 22372916
[TBL] [Abstract][Full Text] [Related]
13. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
15. Lipid-based formulations for oral administration of poorly water-soluble drugs.
Mu H; Holm R; Müllertz A
Int J Pharm; 2013 Aug; 453(1):215-24. PubMed ID: 23578826
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications.
Jaspart S; Piel G; Delattre L; Evrard B
Expert Opin Drug Deliv; 2005 Jan; 2(1):75-87. PubMed ID: 16296736
[TBL] [Abstract][Full Text] [Related]
17. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
Porter CJ; Trevaskis NL; Charman WN
Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
[TBL] [Abstract][Full Text] [Related]
18. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
19. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.
Pouton CW
Eur J Pharm Sci; 2000 Oct; 11 Suppl 2():S93-8. PubMed ID: 11033431
[TBL] [Abstract][Full Text] [Related]
20. Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity.
Jannin V; Chevrier S; Michenaud M; Dumont C; Belotti S; Chavant Y; Demarne F
Int J Pharm; 2015 Nov; 495(1):385-392. PubMed ID: 26364710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
